Replies to post #207318 on Biotech Values

[biotech_researcher]

"A telling stat: The average proportion of insider money participating in 2016 biotech IPOs was 40%—double the average proportion during 2014-2015."

Wow, that says it all.. thanks..

[ghmm]

unfortunately one I wish was down from their IPO price and probably one of the only exceptions is BOLD. Its very thinly traded but is up from its $15 IPO price this summer.
http://www.streetinsider.com/IPOs/Audentes+Therapeutics+(BOLD)+IPO+Prices+at+$15,+Middle+of+Range/11845653.html

I've been following it for a while and seems its held up when other GT players have weakened (perhaps being so thin). Its still quite early so I'd like to see a bit more data especially at this price. Some of the preclinical data seemed compelling in 2 of their programs.